Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy

NCT05394740 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Esophageal Adenocarcinoma

Interventions

DRUG: Regorafenib
DRUG: Nivolumab
DRUG: CapeOX
DRUG: FOLFOX regimen

Sponsor

National Cancer Center Hospital East

Collaborators

[object Object]